Oral Corticosterone Administration Reduces Insulitis but Promotes Insulin Resistance and Hyperglycemia in Male Nonobese Diabetic Mice

American Journal of Pathology

Volumn 187, Issue 3, 2017, Pages 614-626

  Burke, Susan J ^a   Batdorf, Heidi M ^a   Eder, Adrianna E ^b   Karlstad, Michael D ^b   Burk, David H ^a   Noland, Robert C ^a   Floyd, Z Elizabeth ^a   Collier, J Jason ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CITRATE SYNTHASE; COMPLEMENTARY DNA; CORTICOSTERONE; GLUCOSE; GLYCOGEN SYNTHASE; INSULIN; RNA; GLYCOGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCOGEN ANALYSIS; HYPERGLYCEMIA; IMMUNOBLOTTING; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; INSULITIS; LEAN BODY WEIGHT; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SKELETAL MUSCLE; TREATMENT DURATION; ANIMAL; BIOLOGICAL MODEL; BLOOD; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NONOBESE DIABETIC MOUSE; ORAL DRUG ADMINISTRATION; PANCREAS ISLET; PATHOLOGY; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD3; BODY COMPOSITION; CITRATE (SI)-SYNTHASE; CORTICOSTERONE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLYCOGEN; GLYCOGEN SYNTHASE; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; MICE, INBRED NOD; MODELS, BIOLOGICAL; PHENOTYPE; RATS; THINNESS;

EID: 85013175497     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2016.11.009     Document Type: Article

References (64)

1. 1 Atkinson, M.A., Eisenbarth, G.S., Michels, A.W., Type 1 diabetes. Lancet 383 (2014), 69–82.
2. 2 Wasserfall, C., Nead, K., Mathews, C., Atkinson, M.A., The threshold hypothesis: solving the equation of nurture vs nature in type 1 diabetes. Diabetologia 54 (2011), 2232–2236.
3. 3 Fourlanos, S., Harrison, L.C., Colman, P.G., The accelerator hypothesis and increasing incidence of type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 15 (2008), 321–325.
4. 4 Dahlquist, G., Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis. Diabetologia 49 (2006), 20–24.
5. 5 Wilkin, T.J., The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes. Int J Obes (Lond) 33 (2009), 716–726.
6. 6 Diana, J., Simoni, Y., Furio, L., Beaudoin, L., Agerberth, B., Barrat, F., Lehuen, A., Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med 19 (2013), 65–73.
7. 7 Wallberg, M., Cooke, A., Immune mechanisms in type 1 diabetes. Trends Immunol 34 (2013), 583–591.
8. 8 Burke, S.J., Collier, J.J., Insulitis and diabetes: a perspective on islet inflammation. Immunome Res, 10, 2014 Special Issue: Cytokine Biology.
9. 9 Lehuen, A., Diana, J., Zaccone, P., Cooke, A., Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol 10 (2010), 501–513.
10. 10 Lopes, M., Kutlu, B., Miani, M., Bang-Berthelsen, C.H., Storling, J., Pociot, F., Goodman, N., Hood, L., Welsh, N., Bontempi, G., Eizirik, D.L., Temporal profiling of cytokine-induced genes in pancreatic beta-cells by meta-analysis and network inference. Genomics 103 (2014), 264–275.
11. 11 Burke, S.J., Collier, J.J., Transcriptional regulation of chemokine genes: a link to pancreatic islet inflammation?. Biomolecules 5 (2015), 1020–1034.
12. 12 Collier, J.J., Fueger, P.T., Hohmeier, H.E., Newgard, C.B., Pro- and antiapoptotic proteins regulate apoptosis but do not protect against cytokine-mediated cytotoxicity in rat islets and beta-cell lines. Diabetes 55 (2006), 1398–1406.
13. 13 Rehman, K.K., Bertera, S., Bottino, R., Balamurugan, A.N., Mai, J.C., Mi, Z., Trucco, M., Robbins, P.D., Protection of islets by in situ peptide-mediated transduction of the Ikappa B kinase inhibitor Nemo-binding domain peptide. J Biol Chem 278 (2003), 9862–9868.
14. 14 Steer, S.A., Scarim, A.L., Chambers, K.T., Corbett, J.A., Interleukin-1 stimulates beta-cell necrosis and release of the immunological adjuvant HMGB1. PLoS Med, 3, 2006, e17.
15. 15 Collier, J.J., Burke, S.J., Eisenhauer, M.E., Lu, D., Sapp, R.C., Frydman, C.J., Campagna, S.R., Pancreatic beta-cell death in response to pro-inflammatory cytokines is distinct from genuine apoptosis. PLoS One, 6, 2011, e22485.
16. 16 Burke, S.J., Stadler, K., Lu, D., Gleason, E., Han, A., Donohoe, D.R., Rogers, R.C., Hermann, G.E., Karlstad, M.D., Collier, J.J., IL-1beta reciprocally regulates chemokine and insulin secretion in pancreatic beta-cells via NF-kappaB. Am J Physiol Endocrinol Metab 309 (2015), E715–E726.
17. 17 Kadmiel, M., Cidlowski, J.A., Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci 34 (2013), 518–530.
18. 18 Goday, A., Pujol-Borrell, R., Fernandez, J., Casamitjana, R., Rios, M., Vilardell, E., Gomis, R., Effects of a short prednisone regime at clinical onset of type 1 diabetes. Diabetes Res Clin Pract 20 (1993), 39–46.
19. 19 Secchi, A., Pastore, M.R., Sergi, A., Pontiroli, A.E., Pozza, G., Prednisone administration in recent onset type I diabetes. J Autoimmun 3 (1990), 593–600.
20. 20 Kauh, E.A., Mixson, L.A., Shankar, S., McCarthy, J., Maridakis, V., Morrow, L., Heinemann, L., Ruddy, M.K., Herman, G.A., Kelley, D.E., Hompesch, M., Short-term metabolic effects of prednisone administration in healthy subjects. Diabetes Obes Metab 13 (2011), 1001–1007.
21. 21 Burke, S.J., Karlstad, M.D., Collier, J.J., Pancreatic islet responses to metabolic trauma. Shock 46 (2016), 230–238.
22. 22 Beard, J.C., Halter, J.B., Best, J.D., Pfeifer, M.A., Porte, D. Jr., Dexamethasone-induced insulin resistance enhances B cell responsiveness to glucose level in normal men. Am J Physiol 247 (1984), E592–E596.
23. 23 Tamez-Perez, H.E., Quintanilla-Flores, D.L., Rodriguez-Gutierrez, R., Gonzalez-Gonzalez, J.G., Tamez-Pena, A.L., Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes 6 (2015), 1073–1081.
24. 24 Rafacho, A., Ortsater, H., Nadal, A., Quesada, I., Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes. J Endocrinol 223 (2014), R49–R62.
25. 25 Perez, A., Jansen-Chaparro, S., Saigi, I., Bernal-Lopez, M.R., Minambres, I., Gomez-Huelgas, R., Glucocorticoid-induced hyperglycemia. J Diabetes 6 (2014), 9–20.
26. 26 Kwon, S., Hermayer, K.L., Glucocorticoid-induced hyperglycemia. Am J Med Sci 345 (2013), 274–277.
27. 27 Wicks, S.E., Vandanmagsar, B., Haynie, K.R., Fuller, S.E., Warfel, J.D., Stephens, J.M., Wang, M., Han, X., Zhang, J., Noland, R.C., Mynatt, R.L., Impaired mitochondrial fat oxidation induces adaptive remodeling of muscle metabolism. Proc Natl Acad Sci U S A 112 (2015), E3300–E3309.
28. 28 Burke, S.J., Karlstad, M.D., Eder, A.E., Regal, K.M., Lu, D., Burk, D.H., Collier, J.J., Pancreatic beta-cell production of CXCR3 ligands precedes diabetes onset. Biofactors 42:6 (2016), 703–715.
29. 29 Hohmeier, H.E., Mulder, H., Chen, G., Henkel-Rieger, R., Prentki, M., Newgard, C.B., Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 49 (2000), 424–430.
30. 30 Burke, S.J., Karlstad, M.D., Regal, K.M., Sparer, T.E., Lu, D., Elks, C.M., Grant, R.W., Stephens, J.M., Burk, D.H., Collier, J.J., CCL20 is elevated during obesity and differentially regulated by NF-kappaB subunits in pancreatic beta-cells. Biochim Biophys Acta 1849 (2015), 637–652.
31. 31 Vermeulen, J., De Preter, K., Lefever, S., Nuytens, J., De Vloed, F., Derveaux, S., Hellemans, J., Speleman, F., Vandesompele, J., Measurable impact of RNA quality on gene expression results from quantitative PCR. Nucleic Acids Res, 39, 2011, e63.
32. 32 Karatsoreos, I.N., Bhagat, S.M., Bowles, N.P., Weil, Z.M., Pfaff, D.W., McEwen, B.S., Endocrine and physiological changes in response to chronic corticosterone: a potential model of the metabolic syndrome in mouse. Endocrinology 151 (2010), 2117–2127.
33. 33 Connaughton, S., Chowdhury, F., Attia, R.R., Song, S., Zhang, Y., Elam, M.B., Cook, G.A., Park, E.A., Regulation of pyruvate dehydrogenase kinase isoform 4 (PDK4) gene expression by glucocorticoids and insulin. Mol Cell Endocrinol 315 (2010), 159–167.
34. 34 McClain, D.A., Crook, E.D., Hexosamines and insulin resistance. Diabetes 45 (1996), 1003–1009.
35. 35 Rossoll, W., Jablonka, S., Andreassi, C., Kroning, A.K., Karle, K., Monani, U.R., Sendtner, M., Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J Cell Biol 163 (2003), 801–812.
36. 36 Jayasimhan, A., Mansour, K.P., Slattery, R.M., Advances in our understanding of the pathophysiology of type 1 diabetes: lessons from the NOD mouse. Clin Sci (Lond) 126 (2014), 1–18.
37. 37 Mandrup-Poulsen, T., Pickersgill, L., Donath, M.Y., Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 6 (2010), 158–166.
38. 38 Grewal, I.S., Flavell, R.A., New insights into insulin dependent diabetes mellitus from studies with transgenic mouse models. Lab Invest 76 (1997), 3–10.
39. 39 Hu, C., Ding, H., Li, Y., Pearson, J.A., Zhang, X., Flavell, R.A., Wong, F.S., Wen, L., NLRP3 deficiency protects from type 1 diabetes through the regulation of chemotaxis into the pancreatic islets. Proc Natl Acad Sci U S A 112 (2015), 11318–11323.
40. 40 van Raalte, D.H., Diamant, M., Steroid diabetes: from mechanism to treatment?. Neth J Med 72 (2014), 62–72.
41. 41 Hwang, J.L., Weiss, R.E., Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev 30 (2014), 96–102.
42. 42 Siddiqui, A., Madhu, S.V., Sharma, S.B., Desai, N.G., Endocrine stress responses and risk of type 2 diabetes mellitus. Stress 18 (2015), 498–506.
43. 43 Olefsky, J.M., Kimmerling, G., Effects of glucocorticoids on carbohydrate metabolism. Am J Med Sci 271 (1976), 202–210.
44. 44 Kang, S., Tsai, L.T., Rosen, E.D., Nuclear mechanisms of insulin resistance. Trends Cell Biol 26 (2016), 341–351.
45. 45 Hebert, L.F. Jr., Daniels, M.C., Zhou, J., Crook, E.D., Turner, R.L., Simmons, S.T., Neidigh, J.L., Zhu, J.S., Baron, A.D., McClain, D.A., Overexpression of glutamine:fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. J Clin Invest 98 (1996), 930–936.
46. 46 Hawkins, M., Barzilai, N., Liu, R., Hu, M., Chen, W., Rossetti, L., Role of the glucosamine pathway in fat-induced insulin resistance. J Clin Invest 99 (1997), 2173–2182.
47. 47 Long, W., Wei, L., Barrett, E.J., Dexamethasone inhibits the stimulation of muscle protein synthesis and PHAS-I and p70 S6-kinase phosphorylation. Am J Physiol Endocrinol Metab 280 (2001), E570–E575.
48. 48 Pantoja, C., Huff, J.T., Yamamoto, K.R., Glucocorticoid signaling defines a novel commitment state during adipogenesis in vitro. Mol Biol Cell 19 (2008), 4032–4041.
49. 49 Fransson, L., Franzen, S., Rosengren, V., Wolbert, P., Sjoholm, A., Ortsater, H., beta-Cell adaptation in a mouse model of glucocorticoid-induced metabolic syndrome. J Endocrinol 219 (2013), 231–241.
50. 50 Friedline, R.H., Ko, H.J., Jung, D.Y., Lee, Y., Bortell, R., Dagdeviren, S., Patel, P.R., Hu, X., Inashima, K., Kearns, C., Tsitsilianos, N., Shafiq, U., Shultz, L.D., Lee, K.W., Greiner, D.L., Kim, J.K., Genetic ablation of lymphocytes and cytokine signaling in nonobese diabetic mice prevents diet-induced obesity and insulin resistance. FASEB J 30 (2016), 1328–1338.
51. 51 Frazier, B., Hsiao, C.W., Deuster, P., Poth, M., African Americans and Caucasian Americans: differences in glucocorticoid-induced insulin resistance. Horm Metab Res 42 (2010), 887–891.
52. 52 van Rossum, E.F., Lamberts, S.W., Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog Horm Res 59 (2004), 333–357.
53. 53 Baggiolini, M., Chemokines and leukocyte traffic. Nature 392 (1998), 565–568.
54. 54 Arima, Y., Harada, M., Kamimura, D., Park, J.H., Kawano, F., Yull, F.E., Kawamoto, T., Iwakura, Y., Betz, U.A., Marquez, G., Blackwell, T.S., Ohira, Y., Hirano, T., Murakami, M., Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier. Cell 148 (2012), 447–457.
55. 55 Schutyser, E., Struyf, S., Van Damme, J., The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 14 (2003), 409–426.
56. 56 Carr, M.W., Roth, S.J., Luther, E., Rose, S.S., Springer, T.A., Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 91 (1994), 3652–3656.
57. 57 Calderon, B., Suri, A., Unanue, E.R., In CD4+ T-cell-induced diabetes, macrophages are the final effector cells that mediate islet beta-cell killing: studies from an acute model. Am J Pathol 169 (2006), 2137–2147.
58. 58 Medicherla, S., Protter, A.A., Ma, J.Y., Mangadu, R., Almirez, R., Koppelman, B., Kerr, I., Navas, T.A., Movius, F., Reddy, M., Liu, Y.W., Luedtke, G., Perumattam, J., Mavunkel, B., Dugar, S., Schreiner, G.F., Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes. J Pharmacol Exp Ther 318 (2006), 99–107.
59. 59 Burke, S.J., Goff, M.R., Updegraff, B.L., Lu, D., Brown, P.L., Minkin, S.C. Jr., Biggerstaff, J.P., Zhao, L., Karlstad, M.D., Collier, J.J., Regulation of the CCL2 gene in pancreatic beta-cells by IL-1beta and glucocorticoids: role of MKP-1. PLoS One, 7, 2012, e46986.
60. 60 Weinstein, D.S., Gong, H., Doweyko, A.M., Cunningham, M., Habte, S., Wang, J.H., Holloway, D.A., Burke, C., Gao, L., Guarino, V., Carman, J., Somerville, J.E., Shuster, D., Salter-Cid, L., Dodd, J.H., Nadler, S.G., Barrish, J.C., Azaxanthene based selective glucocorticoid receptor modulators: design, synthesis, and pharmacological evaluation of (S)-4-(5-(1-((1,3,4-thiadiazol-2-yl)amino)-2-methyl-1-oxopropan-2-yl)-5H-chromeno[2,3-b]pyridin-2-yl)-2-fluoro-N,N-dimethylbenzamide (BMS-776532) and its methylene homologue (BMS-791826). J Med Chem 54 (2011), 7318–7333.
61. 61 Yates, C.M., Brown, P.J., Stewart, E.L., Patten, C., Austin, R.J., Holt, J.A., Maglich, J.M., Angell, D.C., Sasse, R.Z., Taylor, S.J., Uings, I.J., Trump, R.P., Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists. J Med Chem 53 (2010), 4531–4544.
62. 62 Burke, S.J., May, A.L., Noland, R.C., Lu, D., Brissova, M., Powers, A.C., Sherrill, E.M., Karlstad, M.D., Campagna, S.R., Stephens, J.M., Collier, J.J., Thiobenzothiazole-modified hydrocortisones display anti-inflammatory activity with reduced impact on islet beta-cell function. J Biol Chem 290 (2015), 13401–13416.
63. 63 Atkinson, M.A., Maclaren, N.K., Luchetta, R., Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 39 (1990), 933–937.
64. 64 Gotfredsen, C.F., Buschard, K., Frandsen, E.K., Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 28 (1985), 933–935.